賽特瑞恩068270.KS

賽特瑞恩修正2026年第二季財報，確認創紀錄營業利益4,300億韓元

賽特瑞恩於7月27日提交DART修正申報，確認2026年第二季創紀錄業績：營收1.3兆韓元（年增35.2%）、營業利益4,300億韓元（年增77.3%），利益率達33%。新生物相似藥Zymfentra與Steqeyma合計銷售占比已逾60%；分析師平均目標價為265,333韓元（潛在漲幅37.6%）。

Alteogen ALT-B4 Powers Keytruda SC as Celltrion and Samsung Bioepis Field Rival Korean SC Platforms

Alteogen ALT-B4 powers Keytruda SC with up to $890M MSD milestones. Celltrion and Samsung Bioepis now field rival Korean SC platforms ahead of Keytruda's 2028 patent cliff.

Celltrion (068270.KS) Eyes $5B Tremfya with Phase 1 Trial

Celltrion, one of South Korea's leading biosimilar developers (068270.KS), said on July 15 it has won approval from the MFDS — South Korea's Ministry of Food an

Celltrion Halts EU Keytruda Biosimilar Trial and Trims FDA Study to 220 Patients as Global Regulators Ease Phase 3 Rules

Celltrion halted its EU Phase 3 clinical trial for CT-P51 (Keytruda biosimilar) on July 14 and reduced its FDA trial enrollment from 606 to 220 patients, responding to global regulatory shifts that allow biosimilar approvals with smaller or no Phase 3 data.

Celltrion (068270.KS): Q2 Op Profit Up 77%, Shares Down 20%

Celltrion (068270.KS), South Korea's largest biosimilar maker, reported preliminary second-quarter 2026 results on July 3 showing operating profit up 77.3% to ₩

Samsung, SK Hynix and Celltrion Pledge KRW 392 Trillion to Chungcheong in Korea's 'Second Tokyo Declaration'

Samsung, SK Hynix CEO Kwak No-jeong and Celltrion commit KRW 392 trillion to Chungcheong as President Lee calls it Korea's 'second Tokyo Declaration.' Anthropic also eyes Samsung 2nm foundry.

Celltrion (068270.KS) Q2: Margin 33%, Record ₩430B Profit

Celltrion (068270.KS), Korea's largest biosimilar maker, said its second-quarter operating margin leapt to roughly 33% — the sharpest profitability move in the

Celltrion Remsima SC Commands 31% EU5 Market Share as Phase 3 Crohn's Data Affirms 44-Week Efficacy

Celltrion presented 44-week Remsima SC Phase 3 Crohn's data at AOCC&IMKASID 2026 in Seoul. The subcutaneous biosimilar holds a 31% EU5 market share in Q4 2025 and US Zimpetra prescriptions tripled in Q1 2026 year-on-year.

Korea Unveils First-Ever 'Korea Rising' Session at BIO 2026 as Celltrion Bets on AI-Drug Pivot and ABL Bio Eyes Global Licensing

Korea debuts 'Korea Rising' session at BIO 2026 as Celltrion pivots to AI drugs and ABL Bio seeks global licensing deals, while KB Investment warns Korean biotechs to form US subsidiaries to access institutional capital.

U.S. Poised to Scrap Biosimilar’s ‘Interchangeable’ Hurdle — Celltrion and Samsung Bioepis Stand to Gain Most

The bipartisan Biosimilar Red Tape Elimination Act (S.1954) and parallel FDA guidance would cut Korean drug makers’ development costs 70–90% and shorten timelines by up to four years.

Celltrion Adds Two Cancer Biosimilars in Vietnam

Celltrion is widening its footprint in Vietnam, a small but fast-growing Southeast Asian market — a move that tells investors more about strategy than about this quarter's revenue.

Celltrion Touts HER2 Bispecific Cancer Data, Eyes FDA Fast-Track in 2026

Celltrion (068270.KS), one of South Korea's two largest biopharmaceutical companies by revenue alongside Samsung Biologics and best known for biosimil

Celltrion (068270.KS) Nears ₩2 Trillion Cancellation Goal

Celltrion's First-Ever Union Lands as Record Margins Peak

Celltrion (068270.KS), the Incheon-based biosimilar maker that is South Korea's largest by sales, saw workers form the first labor union in its history on June 1, ending a no-union stretch that has held since the company's 2002 founding (Yonhap; Korea Times). The timing is what matters to investors: the union arrives weeks after Celltrion booked the most profitable year it has ever reported.

Samsung Bio Strike Hardens; Celltrion Forms First Union

Celltrion (068270.KS), South Korea's largest biosimilar developer, said its workers launched a labor union on June 1 — the first in the company's history since founder Seo Jung-jin started it in 2002, according to Chosun Biz and The Korea Times. The move lands as a separate dispute at Samsung Biolog

Celltrion (068270.KS) Adds ₩200B to 2026 Buyback as 0.05 Bonus Issue Sets June Listing

Celltrion added a ₩100B treasury buyback plus a ₩100B parent purchase on May 21, lifting 2026 cancellations toward ~₩2T as a 0.05 bonus issue lists 10.92M shares.

Celltrion (068270.KS) Buys France's Gifrer to Tap 9,000 Pharmacies

Celltrion (068270.KS), Korea's largest biosimilar maker, said on May 12 it has acquired 100% of Gifrer, a 1912-founded French over-the-counter (OTC) and pharmacy pro

Celltrion (068270.KS) Q1 Profit Doubles on Biosimilar Surge

Celltrion's Q1 operating profit more than doubled to 321.9 billion won as biosimilar sales drove revenue up 28% to a record 1.145 trillion won.

Biosimilar M&A Tests Celltrion (068270.KS), Samsung Bioepis

Celltrion Launches Tocilizumab Biosimilar Avtozma in Japan, Expanding Autoimmune Portfolio to Four